TEL AVIV, Israel, January 24, 2019 /PRNewswire/ --
Alvit LCS Pharma, a medical cannabis company specializing in pharma grade products and drug delivery technologies, is a dedicated sponsor of Cannatech's exclusive Canada Cannabis House in Davos, Switzerland. Alvit's CEO Yona Levy presented during the January 24th "Cannabis Innovation" pogram and is participating in various VIP events at the gathering.
CEO Levy released the following statement:
"Alvit is honored to participate and present at this event with such international prestige. We expect to both nurture and cultivate a number of key relationships with industry leaders, while displaying our various products and technologies, thus bolstering Alvit internationally."
Saul Kaye, CEO of iCAN and a co-sponsor of the Canada Cannabis House, added: "A serious discussion in Davos with the global cannabis leadership is an important next step in pushing medicalization forward. We are thrilled to have Alvit as sponsors and to benefit from Yona Levy's expertise and insights. Specialist pharma grade cannabis companies like Alvit will lead the way to better patient access and medical care for all."
The Canada Cannabis House pavilion has a renowned group of presenters and attendees, including Ehud Barak, Former Israeli Prime Minister and Chairman of InterCure; Eyal Barrad, CEO of Cannabics; Lorne Gertner, Chairman of Hiku Brands; Bruce Linton, CEO of Canopy Growth Corp; Jason Warnock, CEO of TheraCann; and Saul Kaye, CEO of iCAN, Israel Cannabis.
About Alvit LCS Pharma
Alvit LCS Pharma is an international leader in the development of products based on standardized cannabis extracts. Alvit's products are differentiated by the fact that they have undergone clinical trials to prove their efficacy and bioavailability. These pharma grade, clinically tested products speak the language of doctors, allowing them to know how much cannabis is being delivered to the body, how much is being absorbed into the body, and for what duration it is effective in the body, providing them the knowledge they need to more effectively prescribe cannabis to patients. In Israel, Alvit directly controls a cannabis research license, and through its Israeli subsidiary Tefen (TLV:TEFN) controls cannabis licenses for propagation and cultivation.
Contact: Laura Lam, email@example.com, +972-54-806-8613
SOURCE Alvit LCS Pharma